|United States Of America||Published Application||20180251730||09/06/2018||2016-018|
|Patent Cooperation Treaty||Published Application||WO2017062374||04/13/2017||2016-018|
Cell replacement therapies using have long been thought to have the potential to treat demyelinating diseases such as multiple sclerosis or hypomyelinating leukodystrophies - as well as spinal cord and other CNS injuries that involve inflammation and loss of myelin. While pluripotent stem cells represent a potential source of readily available regenerative tissue, they require labor-intensive culturing to differentiate into target cell types. Since Oligodendrocyte precursors cells (OPCs) can migrate, engraft and differentiate when experimentally transplanted onto unmyelinated axons, OPCs have been seen as the future of cell replacement therapies for demyelinating diseases. However, as there is currently no reliable and sustainable source of transplantable OPCs, their therapeutic potential cannot be harnessed.
Researchers at the UC Berkeley have created a 3-dimensional, chemically defined biomaterial system for the large-scale differentiation of OPCs. By systematically optimized chemical cues, this strategy rapidly generated Olig2 and NKX2.2-positive cells with the same efficiency of other protocols, but in a shorter period of time (approximately 18 days instead of 30). This shortened 3D differentiation protocol, which results in up to 2-4 times more cells, enables a significant reduction in the cost of production of pre-OPCs.
stem cells, oligodendocyte, cell replacement, therapeutics